Condition: Oligometastasis · Metastatic Cancer · Sponsor: Duke University
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
This description comes directly from the study's public registry record.
Clinical Trials Office · (919) 668 3726 · RadOnc-Clinical_Trials@dm.duke.edu
Always discuss trial participation with your own doctor first.
| Duke Cancer Institute Cary | Cary, North Carolina, United States | Recruiting |
| Durham Veterans Administration Health Care System (DVAHCS) | Durham, North Carolina, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
| Duke Women's Cancer Care Raleigh | Raleigh, North Carolina, United States | Recruiting |
| Duke Raleigh Hospital | Raleigh, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04085029